AB217545

Anti-TAK1 antibody

Name: Anti-TAK1 antibody (ab217545) | Abcam
Brand: Abcam Limited
SKU: AB217545
Price: 525 USD
Availability: InStock

Be the first to review this product! Submit a review

(1 Publication)

Rabbit Polyclonal TAK1 antibody. Suitable for IHC-P and reacts with Rat, Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human MAP3K7 aa 550-600 conjugated to Keyhole Limpet Haemocyanin.

View Alternative Names

TAK1, MAP3K7, Mitogen-activated protein kinase kinase kinase 7, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1

2 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TAK1 antibody (AB217545)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TAK1 antibody (AB217545)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human colon cancer tissue labeling TAK1 with ab217545 at 1/100 dilution, followed by conjugation to the secondary antibody and DAB staining.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TAK1 antibody (AB217545)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded rat brain tissue labeling TAK1 with ab217545 at 1/200 dilution, followed by conjugation to the secondary antibody and DAB staining.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Rat, Human

Applications

IHC-P

applications

Immunogen

Synthetic Peptide within Human MAP3K7 aa 550-600 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

O43318

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/500", "IHCP-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/500", "IHCP-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TAK1 also known as MAP3K7 (Mitogen-activated protein kinase kinase kinase 7) is an important protein kinase that weighs approximately 63 kDa. This protein is expressed in various tissues and cells including HEK 293T cells. TAK1 plays a mechanical role as a part of the MAPK signaling cascade. It phosphorylates and activates downstream kinases which is key to transmitting cellular signals that regulate responses to external stimuli like cytokines and stress.

Biological function summary

TAK1 is involved in several cellular processes necessary for maintaining balance and responding to stress. TAK1 forms a complex with proteins like TAB1 TAB2 and TAB3 which are important for its activation and signaling function. This complex facilitates TAK1's involvement in inflammation and immune response indicating its significance in mediating cellular survival and apoptosis.

Pathways

TAK1 operates within the NF-κB and MAPK pathways two critical routes for cellular response to inflammation and stress. In the NF-κB pathway TAK1 activates IKK which triggers the degradation of IκB freeing NF-κB to move into the nucleus and activate transcription. In the MAPK pathway TAK1 directly influences JNK and p38 cascades revealing regulatory connections to proteins like MEK and ERK.

TAK1 has been linked to conditions such as cancer and inflammatory diseases. In cancers aberrant TAK1 activity can lead to enhanced cell proliferation and survival. Moreover inflammation-related disorders can arise from malfunctioning TAK1 signaling demonstrating its connection to proteins like TNF receptor-associated factors which are involved in inflammatory responses. Understanding TAK1's role in these disorders may pave the way for developing potential therapeutic interventions.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Plays an important role in the cascades of cellular responses evoked by changes in the environment (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR) (PubMed : 16893890, PubMed : 9079627). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7 (PubMed : 11460167, PubMed : 8663074). These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs); both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1) (PubMed : 11460167, PubMed : 12589052, PubMed : 8663074). Independently of MAP2Ks and p38 MAPKs, acts as a key activator of NF-kappa-B by promoting activation of the I-kappa-B-kinase (IKK) core complex (PubMed : 12589052, PubMed : 8663074). Mechanistically, recruited to polyubiquitin chains of RIPK2 and IKBKG/NEMO via TAB2/MAP3K7IP2 and TAB3/MAP3K7IP3, and catalyzes phosphorylation and activation of IKBKB/IKKB component of the IKK complex, leading to NF-kappa-B activation (PubMed : 10094049, PubMed : 11460167). In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B (PubMed : 16893890). Promotes TRIM5 capsid-specific restriction activity (PubMed : 21512573). Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis (By similarity). Phosphorylates STING1 in response to cGAMP-activation, promoting association between STEEP1 and STING1 and STING1 translocation to COPII vesicles (PubMed : 37832545).

See full target information MAP3K7

style

left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in oncology 13:1175183 PubMed37637034

2023

Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaolong Jia,Dongxu Zhang,Cheng Zhou,Zejun Yan,Zhaohui Jiang,Liping Xie,Junhui Jiang

View all publications

style

left-column

style

left-column

style

right-column